



## The Story of Successful Drugs and Recent FDA-Approved Molecules

Guest Editors:

**Dr. Jean Jacques Vanden Eynde**

**Prof. Dr. Klaus Kopka**

**Dr. Maria Emília De Sousa**

**Dr. Annie Mayence**

**Prof. Dr. Joachim Jose**

**Prof. Dr. Guangshun Wang**

Deadline for manuscript  
submissions:

**closed (31 December 2022)**

### Message from the Guest Editors

Dear Colleagues,

In 2018, the FDA approved 59 novel drugs, a record high, demonstrating the vigor of pharmaceutical industry and associated research groups. Small molecules were the most represented entities among the approvals, but there is an increasing number of antibodies and oligonucleotides on the medical market. Interestingly, there is a growing interest in the development of orphan drugs and the treatment of orphan diseases.

The aim of this Special Issue is to offer to our readers short but comprehensive and updated reviews on compounds recently approved by the FDA and drugs attracting particular attention because of their success.

Dr. Jean Jacques Vanden Eynde  
Prof. Dr. Klaus Kopka  
Prof. Dr. Maria Emília De Sousa  
Dr. Annie Mayence  
Prof. Dr. Joachim Jose  
Dr. Guangshun Wang  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Amélia Pilar Rauter**

Departamento de Química e  
Bioquímica (DQB) e Centro de  
Química Estrutural (CQE),  
Institute of Molecular Sciences,  
Faculdade de Ciências,  
Universidade de Lisboa, Lisboa,  
Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)  
[X@Pharmaceut\\_MDPI](#)